Atopic dermatitis (eczema): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

  NCT02612454· Regeneron Pharmaceuticals· Source

• A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07230860· Janssen Research & Development, LLC· Source

• This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

  NCT07290803· Sanofi· Source

• Cardamom and Topical Roseomonas in Atopic Dermatitis

  NCT06096857· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis

  NCT07905547· Sanofi· Source

• Natural History and Genetics of Food Allergy and Related Conditions

  NCT02504853· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Eli Lilly and Company· Source

• A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

  NCT07223697· Hoffmann-La Roche· Source

• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

  NCT05995964· Pfizer· Source

• A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants

  NCT06268860· Amgen· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Mendelian Randomization Analysis 4
• Gene Expression Profiling 2
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Metabolomics 4
• Mass Spectrometry 1
• Flow Cytometry 4
• Immunohistochemistry 4
• Positron-Emission Tomography 1
• Cohort Studies 27
• Genome-Wide Association Study 4

See which targets of this disease your abstract mentions, and go to the people working on them.